Aligos Therapeutics Inc (ALGS) |
|
21.54 -2.6 (-10.77%)
|
03-05 08:48 |
|
Open: |
24 |
Pre. Close: |
24.14 |
|
High:
|
24.15 |
Low:
|
21.19 |
|
Volume:
|
60,382 |
Market Cap:
|
821M |
|
|
|
|
Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-Ã? agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
24.201 - 24.347 |
24.347 - 24.455 |
|
Low:
|
20.879 - 21.052 |
21.052 - 21.18 |
|
Close:
|
21.311 - 21.568 |
21.568 - 21.76 |
|
Technical analysis |
as of: 2021-03-05 8:06:27 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 34.72  One year: 40.88 |
| Support: |
Support1: 21.19 Support2: 17.63 |
| Resistance: |
Resistance1: 29.72 Resistance2: 35.00 |
| Pivot: |
27.16 |
| Moving Average: |
MA(5): 25.68 MA(20): 26.39
MA(100): MA(250): |
| MACD: |
MACD(12,26): -0.67 Signal(9): -0.15 |
| Stochastic oscillator: |
%K(14,3): 9.91 %D(3): 25.93 |
| RSI: |
RSI(14): 37.15 |
| 52-week: |
High: 37.51 Low: 12.82 Change(%): 45.1 |
| Average Vol(K): |
3-Month: 15821 10-Days: 7148 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.ALGS has closed below the lower band by 1.5%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 0% narrower than normal. |
|
|
Headline News |
Wed, 03 Mar 2021
Mar 03, 2021 - Novo A Buys Praxis Precision Medicines Inc, Aligos Therapeutics Inc, Eargo Inc, Sells Vanguard Total Stock Market ETF, Medtronic PLC, Catalent Inc - GuruFocus.com
Tue, 16 Feb 2021
Feb 16, 2021 - Logos Global Management LP Buys Olema Pharmaceuticals inc, Nkarta Inc, Kinnate Biopharma Inc, Sells Global Blood Therapeutics Inc, Keros Therapeutics Inc, Sarepta Therapeutics Inc - GuruFocus.com
Sat, 16 Jan 2021
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)? - Simply Wall St
Thu, 07 Jan 2021
Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Thu, 17 Dec 2020
Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020 - GlobeNewswire
Mon, 16 Nov 2020
Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD's The Liver Meeting Digital Experience™ 2020 - GlobeNewswire
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
35 |
| Shares Float (M) |
18 |
|
% Held by Insiders
|
15.05 |
|
% Held by Institutions
|
27.47 |
|
Shares Short (K)
|
1,260 |
|
Shares Short P. Month (K)
|
1,450 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.271 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-70 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
-10.84 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
